News - Par Pharmaceutical, BioAlliance Pharma

Filter

Popular Filters

1 to 25 of 30 results

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

01-04-2014

Par Pharmaceutical Companies (NYSE: PRX) has announced the appointment of Terrance Coughlin as chief…

BoardroomPar PharmaceuticalPar PharmaceuticalsPharmaceuticalUSA

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Par Pharmaceutical to acquire JHP Pharmaceutical

21-01-2014

US privately-held Par Pharmaceutical has entered into a definitive agreement to acquire JHP Group Holdings,…

GenericsJHP PharmaceuticalsMergers & AcquisitionsPar Pharmaceutical

Acura Pharma settles with Par and Impax over Oxecta

Acura Pharma settles with Par and Impax over Oxecta

11-10-2013

US specialty pharma firm Acura Pharmaceuticals saw its shares leap as much as 28% after it said that…

Acura PharmaceuticalsGenericsImpax LaboratoriesLicensingNeurologicalNorth AmericaOxectaPar PharmaceuticalPatents

Horizon Pharma in Duexis patent settlement

22-08-2013

Horizon Pharma (Nasdaq: HZNP) says it has entered into settlement and license agreements with Par Pharmaceutical…

Anti-Arthritics/RheumaticsDuexisGenericsHorizon PharmaNorth AmericaPar PharmaceuticalPatentsPharmaceutical

BioAlliance Pharma' Sitavig shows marked efficacy in treating cold sores

29-05-2013

French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has presented positive results of the pharmacokinetic…

Anti-viralsBioAlliance PharmaPharmaceuticalResearchSitavig

BioAlliance updates on Livatag development

14-05-2013

French orphan cancer drug developer BioAlliance Pharma (Euronext Paris: BIO) says that the International…

BioAlliance PharmaLivatagNexavarOncologyPharmaceuticalResearch

BioAlliance Pharma's Sitavig OKed by US FDA for Herpes labialis

16-04-2013

French drugmaker BioAlliance Pharma (Euronext Paris - BIO) has received marketing authorization from…

Anti-viralsBioAlliance PharmaNorth AmericaPharmaceuticalRegulationSitavig

BioAlliance Pharma pursues development plan for Loramyc in Japan through partner Sosei

13-03-2013

French orphan oncology and supportive care specialist BioAlliance Pharma (Euronext Paris: BIO) says its…

Antibiotics and Infectious diseasesAsia-PacificBioAlliance PharmaLoramycOravigPharmaceuticalRegulationResearchSosei

Par Pharma agrees $45 million settlement over off-label Megace ES promotion

07-03-2013

US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

BioAlliance Pharma extends Ph II Validive trial to USA

19-02-2013

French biotech firm BioAlliance Pharma (Euronext Paris - BIO) has announced the extension of its Phase…

BioAlliance PharmaBiotechnologyclonidine LauriadOncologyResearchValidive

BioAlliance says partner Vestiq debuts Oravig in USA

08-01-2013

French biotech firm BioAlliance Pharma (Euronext Paris - BIO) has announces the launch of Oravig (miconazole…

BioAlliance PharmaBiotechnologyLoramycMarkets & MarketingNorth AmericaOncologyOravigPharmaceuticalVestiq Pharmaceuticals

BioAlliance gains registration of Sitavig in eight European countries

20-12-2012

French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the approval of Sitavig (acyclovir…

Anti-viralsBioAlliance PharmaBiotechnologyEuropeRegulationSitavig

Validity of certain patent claims covering Santarus' Zegerid capsule and powder upheld

06-09-2012

US drugmaker Santarus (Nasdaq: SNTS) saw its shares leap 14.2% to $7.06 in regular trading on September…

GenericsLegalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSantarusZegerid

Mylan settles litigation with Somaxon relating to its generic Silenor

19-07-2012

US generic drugmaker Mylan (Nasdaq: MYL) and its subsidiary, Mylan Pharmaceuticals have entered into…

LegalMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalPatentsPharmaceuticalSilenorSomaxon Pharmaceuticals

TPG to acquire Par Pharma for $1.9 billion

17-07-2012

Par Pharmaceutical (NYSE: PRX), a USA-based maker of generic drugs and niche innovative proprietary pharmaceuticals,…

GenericsMergers & AcquisitionsPar PharmaceuticalTPG

Teva gets rights to BioAlliance's Sitavig in Israel

14-06-2012

French drugmaker BioAlliance Pharma (Euronext Paris: BIO) has signed an exclusive license agreement for…

Anti-viralsBioAlliance PharmaLicensingPharmaceuticalRest of the WorldSitavigTeva Pharmaceutical Industries

BioAlliance's Sitavig NDA "receivable" by US FDA

30-05-2012

French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the receivability of its Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyNorth AmericaRegulationSitavigSitavir

BioAlliance Pharma updates on Amep biotherapy development

02-05-2012

its application for a Phase I/II clinical trial with Amep in the metastatic melanoma, and the signing…

AmepBioAlliance PharmaOncologyPharmaceuticalResearch

FDA decides Teva is sole first-to-file on Provigil; Mylan argues ruling

09-04-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) said on April 5 that the US Food and Drug…

CephalonGenericsLegalModafinilMylan LaboratoriesNeurologicalNorth AmericaPar PharmaceuticalProvigilRegulationTeva Pharmaceutical Industries

Horizon Pharma sues Par for infringing Duexis patent

29-03-2012

Horizon Pharma (Nasdaq: HZNP) has filed a patent infringement lawsuit in the US District Court for the…

DuexisGenericsHorizon PharmaLegalNeurologicalNorth AmericaPar PharmaceuticalPatents

NovaDel regains rights for ondansetron oral spray product

22-01-2012

New Jersey, USA-based NovaDel Pharma (OTCBB: NVDL) has announced the termination of certain license agreements…

BioAlliance PharmaLicensingNovaDel PharmaOncologyondansetronPar PharmaceuticalPharmaceuticalTalon Therapeutics

1 to 25 of 30 results

Company Spotlight

Fibrotech

Fibrotech

Back to top